证券代码：603718 证券简称：海利生物 公告编号：2025－040 上海海利生物技术股份有限公司 第五届董事会第十五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 上海海利生物技术股份有限公司（以下简称"公司"）第五届董事会第十五 次会议通知于 2025 年 9 月 5 日以电子邮件和电话方式送达全体董事，于 2025 年 9 月 12 日上午以现场的方式召开。本次董事会会议应参加董事 7 人，实际参 加董事 7 名。本次会议符合《公司法》、《公司章程》和《董事会议事规则》的有 关规定，会议的召集、召开合法有效。 二、董事会会议审议情况 已经公司 2025 年第一次独立董事专门会议审议通过。 同意公司与美伦管理有限公司（以下简称"美伦公司"）签订《关于收购陕西瑞 盛生物科技有限公司 55%股权之交易的补充协议》（以下简称"补充协议"），调整原 收购的交易价格，由人民币 9.35 亿元调整为人民币 53,570 万元，美伦公司将按补充 协议约定返还本次调整后的交易价格差额 39, ...

截至发稿，海利生物市值为46亿元。 每经AI快讯，海利生物（SH 603718，收盘价：7.08元）9月15日晚间发布公告称，公司第五届第十五次 董事会会议于2025年9月12日以现场的方式召开。会议审议了《关于重大资产购买调整交易价格并签署 补充协议的议案》等文件。 2024年1至12月份，海利生物的营业收入构成为：医疗器械占比57.81%，兽用生物制品占比42.19%，其 他业务占比0.01%。 每经头条（nbdtoutiao）——重大突破！中国这款新药，中美官方都认定有突破性疗效！世界肺癌大会 沸腾了 （记者 张喜威） ...

海利生物公告，公司与美伦管理有限公司签订补充协议，调整重大资产购买交易价格。根据北京卓信大 华资产评估有限公司评估，瑞盛生物股东全部权益价值为9.74亿元，比原17亿元下调。因此，交易价格 由9.35亿元调整为5.36亿元，美伦公司将返还交易价格差额3.99亿元。此次调整不影响公司对瑞盛生物 55%股权的持有，有助于降低投资风险和业绩承诺无法达成风险。调整后的2025年和2026年扣非净利润 承诺数分别为5000万元和5800万元。 ...

证券之星消息，9月15日动物保健板块较上一交易日上涨1.14%，生物股份领涨。当日上证指数报收于 3860.5，下跌0.26%。深证成指报收于13005.77，上涨0.63%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600201 | 生物股份 | 8.82 | 7.17% | 62.41万 | 5.39亿 | | 871970 | 大禹生物 | 11.50 | 6.09% | 12.43万 | 1.39亿 | | 838275 | 驱动力 | 11.22 | 3.60% | 2.84万 | 3158.46万 | | 002688 | 金河生物 | 7.20 | 3.00% | 40.77万 | 2.93亿 | | 300119 | 瑞普生物 | 21.98 | 1.76% | 8.09万 | 1.77亿 | | 600195 | 中牧股份 | 7.50 | 1.63% | 11.40万 | 8500.44万 | | 839729 | 永顺生物 | 10.58 ...

从资金流向上来看，当日动物保健板块主力资金净流出1543.66万元，游资资金净流入2447.27万元，散户 资金净流出903.61万元。动物保健板块个股资金流向见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 871970 | 大禹生物 | 10.73 | -3.85% | 7.66万 | 8230.61万 | | 838275 | 驱动力 | 10.80 | -2.26% | 1.55万 | 1676.03万 | | 002141 | 后丰控股 | 4.03 | -1.95% | 23.77万 | 9597.12万 | | 839729 | 永顺生物 | 10.69 | -1.02% | 2.74万 | 2915.24万 | | 603566 | 普莱柯 | 14.51 | -0.75% | 2.59万 | 3755.59万 | | 603718 | 海利生物 | 7.12 | -0.14% | 5.90万 | 4190.82万 | | 600195 | 中牧股份 | 7.41 | - ...

Core Viewpoint - The animal health sector experienced a rise of 0.92% on September 11, with Dayu Biological leading the gains, while the overall market indices also showed significant increases [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 3875.31, up 1.65%, and the Shenzhen Component Index closed at 12979.89, up 3.36% [1]. - Dayu Biological's stock price increased by 3.81% to 11.16, with a trading volume of 140,500 shares and a transaction value of 158 million [1]. Group 2: Individual Stock Performance - Other notable performers included: - Houfeng Holdings, up 2.75% to 4.11, with a trading volume of 326,800 shares and a transaction value of 133 million [1]. - Keqian Biological, up 2.15% to 18.50, with a trading volume of 32,400 shares and a transaction value of 59.27 million [1]. - Yongshun Biological, up 1.69% to 10.80, with a trading volume of 48,100 shares and a transaction value of 52.46 million [1]. Group 3: Capital Flow Analysis - The animal health sector saw a net outflow of 70.71 million from institutional investors, while retail investors contributed a net inflow of 77.65 million [2][3]. - The capital flow for individual stocks showed varied trends, with significant outflows from stocks like Zhongmu Co., which had a net outflow of 11.86 million from institutional investors [3].

证券日报网讯9月10日晚间，海利生物（603718）发布公告称，控股子公司瑞盛生物的三类医疗器械"天 然骨修复材料"注册申请获得国家药监局受理。该产品适用于颌骨缺损修复，采用更高效生产工艺，骨 修复效果更快更稳定。产品获批上市后，将在口腔骨缺损修复领域丰富瑞盛生物的产品线。 ...

Group 1 - Dematech won a 900 million yuan overseas smart logistics project from a well-known e-commerce giant in Latin America, focusing on intelligent logistics cross-belt sorting systems and related services [1] - Kang En Bei received approval for the registration of short-term financing bonds and medium-term notes, with a total registration amount of 1 billion yuan, valid for two years [1][2] - Zhi Xiang Jin Tai's GR1803 injection for systemic lupus erythematosus clinical trial has been approved by the National Medical Products Administration [2] Group 2 - Jin Da Wei's subsidiary received approval for a veterinary drug product, pyridone, valid from September 3, 2025, to September 2, 2030 [4] - Fu Li Wang's subsidiary plans to invest 500 million yuan in a high-end wire material project, focusing on high-strength prestressed steel strands for various applications [5] - He Li Biological's subsidiary's Class III medical device registration application has been accepted, focusing on natural bone repair materials [12] Group 3 - Lin Yang Energy won a 244 million yuan metering equipment project from Southern Power Grid, expected to positively impact its 2025 and 2026 performance [20] - Sanxia Water plans to absorb its wholly-owned subsidiary, Chongqing Changdian United Energy, with all assets and liabilities to be inherited by Sanxia Water [13] - Tian Cheng Technology canceled the use of 91 million yuan of raised funds for permanent working capital, ensuring no impact on the normal operation of investment projects [24] Group 4 - Baosteel received approval to publicly issue bonds totaling 20 billion yuan to professional investors, valid for 24 months [52] - Tian Kang Biological reported a 10.15% year-on-year increase in pig sales in August, with a total of 263,800 pigs sold [53] - Xinjiang Construction won multiple major projects totaling 4.506 billion yuan, including a 2.4 billion yuan photovoltaic hydrogen synthesis project [18]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：603718 证券简称：海利生物 公告编号：2025－039 上海海利生物技术股份有限公司 关于控股子公司三类医疗器械注册申请获得受理的公告 上海海利生物技术股份有限公司（以下简称"公司"）控股子公司陕西瑞盛生物 科技有限公司（以下简称"瑞盛生物"）于近日收到国家药品监督管理局（以下简称 "国家药监局"）下发的医疗器械注册申请受理通知信息，现将相关情况公告如下： 一、该医疗器械的基本信息 申请人：陕西瑞盛生物科技有限公司 产品名称：天然骨修复材料 受理号：CQZ2501670 产品类别：第三类医疗器械 二、 目前所处审批阶段 该医疗器械目前注册申请已获得受理。 三、 后续所需审批流程 后续所需的审批流程：审评审批、制证。 临床用途：适用于颌骨缺损修复 异种骨修复材料因其形态和多孔结构与天然骨相似，有利于骨细胞长入及骨组织 分化形成。通过物理化学方法可去除其免疫原性，具备来源广泛、制造成本低、获取 与加工便捷、生物力学性能优良、能被机体吸收降解等优势，在口腔骨修复市 ...

Market Overview - The animal health sector experienced a decline of 0.5% on September 10, with Yongshun Biological leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Notable gainers included: - Qudongli (838275) with a closing price of 11.21, up 2.75% [1] - *ST Lvkang (002868) at 26.42, up 1.62% [1] - Houfeng Holdings (002141) at 4.00, up 0.76% [1] - Major decliners included: - Yongshun Biological (839729) at 10.62, down 3.28% [2] - Shilian Biological (688098) at 11.72, down 1.76% [2] - Huai Sheng Biological (300871) at 22.20, down 1.60% [2] Capital Flow Analysis - The animal health sector saw a net outflow of 81.6 million yuan from institutional investors, while retail investors contributed a net inflow of 53.0 million yuan [2] - The detailed capital flow for key stocks showed: - Repu Biological (300119) had a net inflow of 1.12 million yuan from retail investors [3] - Kexian Biological (688526) saw a net inflow of 14.78 thousand yuan from institutional investors [3] - Hai Li Biological (603718) experienced a significant net outflow of 22.66 million yuan from institutional investors [3]